Trials / Completed
CompletedNCT00252746
ZD6474 Phase IIa Dose Finding Multicentre Study
A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD6474 (vandetanib) 100mg | once daily oral dose |
| DRUG | ZD6474 (vandetanib) 200mg | once daily oral dose |
| DRUG | ZD6474 (vandetanib) 300mg | once daily oral dose |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-01
- First posted
- 2005-11-15
- Last updated
- 2016-08-25
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00252746. Inclusion in this directory is not an endorsement.